PolarCool AB (publ) has received a final report from the 5-year clinical study conducted in partnership with the SHL and with the support of the players’ union, SICO. The responsible researchers Professor Niklas Marklund and Professor Emeritus Yelverton Tegner have, after the now completed ice hockey season, compiled the final result.

A total of 137 diagnosed concussions were included in the study, further strengthening the clinical evidence supporting the PolarCap® System. Return to Play continues to be significantly shorter among treated players (n = 62) compared to control (n = 75), 9 days for treated and 12 days for control, p <0.0001.

The result also shows a significant reduction in the proportion of absence, at all examined times (1v, 2v, 3v, 4v, 8v, and> 100 days). Not least the long-term absence (3v or more, 6% of treated and 29% in control, p = 0.001).

During the last two seasons follow-up study, symptom development after concussion has also been studied. The results are based on the individuals' Symptom Severity Score (SSS), which is part of SCAT5, show a significant early symptom reduction after cooling treatment.

A more detailed summary of the results can be red in the attached appendix to this press release.

Professor Niklas Marklund, Lund University, responsible researcher comments;

- As a responsible researcher, I see the results as exciting in that they strengthen the already published results from the initial 3-year study. What I see as most interesting and important is the clear reduction in long-term absence after cooling treatment. The ambition is now to publish the results in a scientific journal for dissemination within the medical profession. Overall, I see the results as something that further strengthens the indication for cooling treatment of athletes suffering from concussions.

PolarCool's CEO Erik Andersson comments:

- We note that the new results further strengthen the evidence for the company's product PolarCap® System. Most gratifying is the highly significant effect of the reduction of athletes of long-term absence in the treated group. It is also interesting that the previous indication regarding treatment time now has been strengthened and points to a dose effect. Which means that we will even more recommend users to treat for at least 45 minutes but preferably longer. Overall, the company hopes that this robust evidence that is now presented will provide further acceptance among those in the medical profession who have requested more clinical data regarding the effects of the PolarCap® System.

This information is information that PolarCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on June 28th, 2021.

 For more information

Erik Andersson –  CEO PolarCool AB (publ)               
+46 - 738 60 57 00                                         
E-mail: erik.andersson@polarcool.se 

About PolarCool AB (publ)

PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.